Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Ionis Pharmaceuticals upgraded to Neutral from Sell at UBS » 09:21
05/07/21
05/07
09:21
05/07/21
09:21
IONS

Ionis Pharmaceuticals

$37.34 /

-2.46 (-6.18%)

UBS analyst Esther…

UBS analyst Esther Rajavelu upgraded Ionis Pharmaceuticals to Neutral from Sell with a price target of $37.50, up from $33. With the stock now "fairly reflecting" the risk/reward offered by the company's pipeline and business strategy, the Sell thesis has largely played out, Rajavelu tells investors in a research note. With that said, the analyst continues to model declining revenues and has little visibility on near-term new launches.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$37.34 /

-2.46 (-6.18%)

IONS Ionis Pharmaceuticals
$37.34 /

-2.46 (-6.18%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
IONS Ionis Pharmaceuticals
$37.34 /

-2.46 (-6.18%)

IONS Ionis Pharmaceuticals
$37.34 /

-2.46 (-6.18%)

IONS Ionis Pharmaceuticals
$37.34 /

-2.46 (-6.18%)

Over a week ago
Earnings
Ionis Pharmaceuticals reports Q1 EPS (64c), consensus (46c) » 07:09
05/05/21
05/05
07:09
05/05/21
07:09
IONS

Ionis Pharmaceuticals

$41.95 /

-1.04 (-2.42%)

Reports Q1 revenue $112M,…

Reports Q1 revenue $112M, consensus $128.59M. "In Q1, we took important steps to maximize the value of our wholly owned pipeline. We recently initiated pivotal studies with our wholly owned FUS-ALS and Alexander disease programs. We delivered positive results from our IONIS-PKK-LRx program, demonstrating its potential to change the standard of care for patients with hereditary angioedema. We also further strengthened the business and continued executing on our strategic priorities," said CEO Brett Monia. "This summer, we expect data from our IONIS-MAPTRx program in Alzheimer's disease patients. And later this year, we look forward to data from the Phase 3 VALOR study of tofersen in patients with SOD1-ALS. If results from the VALOR study are positive, we expect tofersen to be our next commercial medicine. These key upcoming catalysts, together with our recent achievements, position us well to have 12 or more products on the market in 2026."

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$41.95 /

-1.04 (-2.42%)

IONS Ionis Pharmaceuticals
$41.95 /

-1.04 (-2.42%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
IONS Ionis Pharmaceuticals
$41.95 /

-1.04 (-2.42%)

IONS Ionis Pharmaceuticals
$41.95 /

-1.04 (-2.42%)

IONS Ionis Pharmaceuticals
$41.95 /

-1.04 (-2.42%)

Hot Stocks
Cathie Wood's ARK Investment buys 308.9K shares of Ionis Pharmaceuticals today  20:58
05/03/21
05/03
20:58
05/03/21
20:58
IONS

Ionis Pharmaceuticals

$42.99 /

+0.19 (+0.44%)

 
ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$42.99 /

+0.19 (+0.44%)

IONS Ionis Pharmaceuticals
$42.99 /

+0.19 (+0.44%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
IONS Ionis Pharmaceuticals
$42.99 /

+0.19 (+0.44%)

IONS Ionis Pharmaceuticals
$42.99 /

+0.19 (+0.44%)

IONS Ionis Pharmaceuticals
$42.99 /

+0.19 (+0.44%)

Conference/Events
Ionis Pharmaceuticals to ho ld a conference call » 11:55
04/23/21
04/23
11:55
04/23/21
11:55
IONS

Ionis Pharmaceuticals

$42.53 /

+0.05 (+0.12%)

Management holds a rare…

Management holds a rare disease conference call on Acromegaly on April 23 at 12 pm. Webcast Link

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$42.53 /

+0.05 (+0.12%)

IONS Ionis Pharmaceuticals
$42.53 /

+0.05 (+0.12%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
IONS Ionis Pharmaceuticals
$42.53 /

+0.05 (+0.12%)

IONS Ionis Pharmaceuticals
$42.53 /

+0.05 (+0.12%)

IONS Ionis Pharmaceuticals
$42.53 /

+0.05 (+0.12%)

Conference/Events
Ionis Pharmaceuticals to ho ld a conference call » 04:55
04/23/21
04/23
04:55
04/23/21
04:55
IONS

Ionis Pharmaceuticals

$42.48 /

+0.96 (+2.31%)

Management holds a rare…

Management holds a rare disease conference call on Acromegaly on April 23 at 12 pm. Webcast Link

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$42.48 /

+0.96 (+2.31%)

IONS Ionis Pharmaceuticals
$42.48 /

+0.96 (+2.31%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
IONS Ionis Pharmaceuticals
$42.48 /

+0.96 (+2.31%)

IONS Ionis Pharmaceuticals
$42.48 /

+0.96 (+2.31%)

IONS Ionis Pharmaceuticals
$42.48 /

+0.96 (+2.31%)

Hot Stocks
Ionis Pharmaceuticals initiates pivotal clinical study of ION373 » 07:05
04/20/21
04/20
07:05
04/20/21
07:05
IONS

Ionis Pharmaceuticals

$39.95 /

-0.81 (-1.99%)

Ionis Pharmaceuticals…

Ionis Pharmaceuticals announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a rare and generally fatal neurological disorder. Alexander disease patients experience progressive deterioration, leading to severe disability and loss of independence. Childhood onset is associated with more serious disease, with patients rarely surviving beyond adolescence. Alexander disease is caused by a genetic mutation that leads to overproduction and toxic accumulation of glial fibrillary acidic protein in the brain. ION373 is an investigational antisense medicine designed to reduce the level of GFAP.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

Conference/Events
Ionis Pharmaceuticals to ho ld a conference call » 16:58
04/19/21
04/19
16:58
04/19/21
16:58
IONS

Ionis Pharmaceuticals

$39.95 /

-0.81 (-1.99%)

Management holds a rare…

Management holds a rare disease conference call on Acromegaly on April 23 at 12 pm. Webcast Link

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

IONS Ionis Pharmaceuticals
$39.95 /

-0.81 (-1.99%)

Over a month ago
Conference/Events
Needham to hold a virtual conference » 09:12
04/12/21
04/12
09:12
04/12/21
09:12
GRCL

Gracell

$13.52 /

-0.82 (-5.72%)

, LMAT

LeMaitre

$51.38 /

+0.82 (+1.62%)

, IONS

Ionis Pharmaceuticals

$42.32 /

-0.32 (-0.75%)

, TSHA

Taysha Gene Therapies

$21.35 /

+1.49 (+7.50%)

, ZEAL

Zealand Pharma

$33.60 /

+1.27 (+3.93%)

, CLSD

Clearside Biomedical

$2.66 /

+0.12 (+4.72%)

, MEIP

MEI Pharma

$3.43 /

+0.12 (+3.63%)

, PCVX

Vaxcyte

$20.27 /

-0.49 (-2.36%)

, EVLO

Evelo Biosciences

$10.03 /

+0.005 (+0.05%)

, IVC

Invacare

$8.23 /

-0.08 (-0.96%)

, BSGM

BioSig Technologies

$4.59 /

+0.12 (+2.68%)

, CYTK

Cytokinetics

$24.17 /

+0.01 (+0.04%)

, SYBX

Synlogic

$3.34 /

-0.02 (-0.60%)

, RNA

Avidity Biosciences

$22.12 /

-1.8 (-7.53%)

, CSTL

Castle Biosciences

$69.44 /

-1.2 (-1.70%)

, AGI

Alamos Gold

$8.37 /

+0.08 (+0.97%)

, CARA

Cara Therapeutics

$29.09 /

+1.645 (+5.99%)

, FIX

Comfort Systems USA

$79.11 /

+1.925 (+2.49%)

, ITRM

Iterum Therapeutics

$1.30 /

-0.305 (-19.00%)

, LTRN

Lantern Pharma

$17.05 /

-0.13 (-0.76%)

, OCGN

Ocugen

$6.96 /

+0.045 (+0.65%)

, QURE

uniQure

$33.77 /

-1.75 (-4.93%)

, STTK

Shattuck Labs

$28.31 /

+1.365 (+5.07%)

, VKTX

Viking Therapeutics

$5.93 /

-0.23 (-3.73%)

20th Annual Virtual…

20th Annual Virtual Healthcare Virtual Conference will be held on April 12-15.

ShowHide Related Items >><<
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

IVC Invacare
$8.23 /

-0.08 (-0.96%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

02/03/21 Citi
Gracell initiated with a Buy at Citi
02/02/21 Jefferies
Gracell initiated with a Buy at Jefferies
02/02/21 Wells Fargo
Gracell initiated with an Overweight at Wells Fargo
02/02/21 Piper Sandler
Gracell initiated with an Overweight at Piper Sandler
LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

02/26/21 Barrington
LeMaitre price target raised to $49 from $47 at Barrington
02/12/21
Fly Intel: Top five analyst initiations
02/12/21 KeyBanc
LeMaitre initiated with a Sector Weight at KeyBanc
02/11/21 KeyBanc
LeMaitre initiated with a Sector Weight at KeyBanc
IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
05/29/20
Fly Intel: Top five analyst initiations
PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
07/07/20
Fly Intel: Top five analyst initiations
07/07/20 BofA
Vaxcyte initiated with a Buy at BofA
07/07/20 Jefferies
Vaxcyte initiated with a Buy at Jefferies
EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

04/12/21 Jefferies
Jefferies upgrades Evelo Biosciences to Buy on increased microbiome momentum
04/12/21 Jefferies
Evelo Biosciences upgraded to Buy from Hold at Jefferies
03/12/21 Chardan
Evelo Biosciences price target raised to $15 from $10 at Chardan
01/25/21 JMP Securities
Evelo Biosciences price target raised to $36 from $27 at JMP Securities
IVC Invacare
$8.23 /

-0.08 (-0.96%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
12/28/20 Oppenheimer
Amgen price target lowered to $266 from $274 at Oppenheimer
SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

03/09/21 Baird
Castle Biosciences price target lowered to $82 from $87 at Baird
02/03/21 KeyBanc
Castle Biosciences price target raised to $90 from $70 at KeyBanc
01/26/21 Canaccord
Castle Biosciences price target raised to $84 from $80 at Canaccord
01/15/21 SVB Leerink
Castle Biosciences price target raised to $80 from $70 at SVB Leerink
AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

02/10/21 JPMorgan
Alamos Gold initiated with a Neutral at JPMorgan
02/08/21 CIBC
Alamos Gold price target lowered to C$16 from C$19.25 at CIBC
02/02/21 National Bank
Alamos Gold price target lowered to C$14.50 from C$15.50 at National Bank
01/11/21 National Bank
Alamos Gold price target lowered to C$15.50 from C$16 at National Bank
CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

12/29/20 H.C. Wainwright
H.C. Wainwright reiterates $33 target on Cara after new drug filing
10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

07/29/20 DA Davidson
Comfort Systems USA price target raised to $45 from $32 at DA Davidson
04/29/20 DA Davidson
Comfort Systems USA downgraded to Neutral from Buy at DA Davidson
04/29/20 DA Davidson
Comfort Systems USA downgraded to Neutral from Buy at DA Davidson
04/20/20 Sidoti
Comfort Systems USA downgraded to Neutral from Buy at Sidoti
ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

03/15/21 H.C. Wainwright
Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
12/24/20 H.C. Wainwright
Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
06/16/20 H.C. Wainwright
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/02/20 RBC Capital
Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

03/31/21
Ocugen participates in a conference call with Cantor Fitzgerald
03/16/21 Roth Capital
Covaxin chances of U.S. approval now increased, says Roth Capital
03/04/21 Roth Capital
Ocugen price target raised to $10 from $9 at Roth Capital
03/04/21 Roth Capital
Roth boosts Ocugen target after partnered vaccine shows 'broad' efficacy
QURE uniQure
$33.77 /

-1.75 (-4.93%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
11/03/20 Citi
Shattuck Labs initiated with a Buy at Citi
VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

02/18/21 Chardan
Chardan trims Viking Therapeutics target to $19 as COVID pushes out Voyage data
09/11/20 B. Riley
Viking Therapeutics price target raised to $15 from $12 at B. Riley FBR
09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

IVC Invacare
$8.23 /

-0.08 (-0.96%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

  • 29
    Jan
  • 15
    Jan
  • 08
    Jan
  • 16
    Dec
  • 09
    Oct
  • 24
    Sep
  • 17
    Jul
  • 25
    Jun
  • 25
    Jun
  • 11
    Jun
  • 12
    Jun
  • 12
    Jun
OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

On The Fly
Fly Intel: After-Hours Movers » 17:55
04/06/21
04/06
17:55
04/06/21
17:55
SGH

Smart Global

$48.71 /

-0.76 (-1.54%)

, NVST

Envista

$40.91 /

-0.82 (-1.97%)

, IDCC

InterDigital

$65.99 /

+0.35 (+0.53%)

, QGEN

Qiagen

$50.00 /

+0.345 (+0.69%)

, MAXN

Maxeon Solar

$28.43 /

-1.76 (-5.83%)

, FGEN

FibroGen

$34.61 /

-0.93 (-2.62%)

, FIXX

Homology Medicines

$9.30 /

-0.34 (-3.53%)

, PHR

Phreesia

$55.13 /

-0.005 (-0.01%)

, IONS

Ionis Pharmaceuticals

$47.25 /

+0.35 (+0.75%)

, LI

Li Auto

$25.52 /

+0.55 (+2.20%)

, OM

Outset Medical

$58.04 /

+1.21 (+2.13%)

Check out this evening's…

ShowHide Related Items >><<
SGH Smart Global
$48.71 /

-0.76 (-1.54%)

QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

PHR Phreesia
$55.13 /

-0.005 (-0.01%)

OM Outset Medical
$58.04 /

+1.21 (+2.13%)

NVST Envista
$40.91 /

-0.82 (-1.97%)

MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

IDCC InterDigital
$65.99 /

+0.35 (+0.53%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

SGH Smart Global
$48.71 /

-0.76 (-1.54%)

02/10/21 Stifel
Smart Global price target raised to $55 from $48 at Stifel
01/06/21 Needham
Smart Global price target raised to $56 from $39 at Needham
01/06/21 Deutsche Bank
Smart Global price target raised to $48 from $44 at Deutsche Bank
01/04/21 Deutsche Bank
Smart Global price target raised to $44 from $35 at Deutsche Bank
NVST Envista
$40.91 /

-0.82 (-1.97%)

02/11/21 Piper Sandler
Envista price target raised to $41 from $28 at Piper Sandler
01/08/21 Credit Suisse
Envista upgraded to Outperform from Neutral at Credit Suisse
10/30/20 JPMorgan
Envista price target raised to $30 from $28 at JPMorgan
10/30/20 Piper Sandler
Envista price target raised to $28 from $22 at Piper Sandler
IDCC InterDigital
$65.99 /

+0.35 (+0.53%)

03/18/21 B. Riley
B. Riley keeps Buy on InterDigital, still sees renewal opportunity with LG
02/19/21 B. Riley
InterDigital price target raised to $123 from $100 at B. Riley Securities
10/08/20 B. Riley
InterDigital settlement with Lenovo now more likely, says B. Riley Securities
08/27/20 B. Riley
U.K. Supreme Court ruling positive for InterDigital, says B. Riley FBR
QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/19/21 Roth Capital
Maxeon Solar initiated with a Buy at Roth Capital
01/04/21 Goldman Sachs
Maxeon Solar price target raised to $18 from $15 at Goldman Sachs
11/10/20 Raymond James
Maxeon Solar upgraded to Outperform at Raymond James on Biden election
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

03/31/21 BofA
BofA upgrades FibroGen to Buy, sees roxadustat approval being 'most likely'
03/31/21 BofA
FibroGen upgraded to Buy from Neutral at BofA
03/02/21
Fly Intel: Top five analyst downgrades
03/02/21 Jefferies
FibroGen downgraded to Hold at Jefferies on increased risk for roxadustat
FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
PHR Phreesia
$55.13 /

-0.005 (-0.01%)

04/01/21 SVB Leerink
Phreesia price target lowered to $75 from $85 at SVB Leerink
04/01/21 Baird
Phreesia initiated with an Outperform at Baird
03/31/21 Piper Sandler
Phreesia price target raised to $58 from $56 at Piper Sandler
03/31/21 KeyBanc
Phreesia price target lowered to $70 from $80 at KeyBanc
IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
LI Li Auto
$25.52 /

+0.55 (+2.20%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 Needham
Li Auto initiated with a Buy at Needham
03/11/21 Needham
Li Auto initiated with a Buy at Needham
03/03/21 Wedbush
China growth story worth at least $100/share in bull case to Tesla, says Wedbush
OM Outset Medical
$58.04 /

+1.21 (+2.13%)

12/15/20 Oppenheimer
Oppenheimer starts Outset Medical at Perform, citing competition
12/15/20 Oppenheimer
Outset Medical initiated with a Perform at Oppenheimer
10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
SGH Smart Global
$48.71 /

-0.76 (-1.54%)

QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

PHR Phreesia
$55.13 /

-0.005 (-0.01%)

OM Outset Medical
$58.04 /

+1.21 (+2.13%)

NVST Envista
$40.91 /

-0.82 (-1.97%)

MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

IDCC InterDigital
$65.99 /

+0.35 (+0.53%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

  • 09
    Apr
  • 07
    Apr
  • 08
    Apr
  • 08
    Jan
  • 04
    Dec
  • 03
    Dec
  • 21
    Oct
  • 15
    Sep
  • 30
    Jul
QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

SGH Smart Global
$48.71 /

-0.76 (-1.54%)

QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

PHR Phreesia
$55.13 /

-0.005 (-0.01%)

OM Outset Medical
$58.04 /

+1.21 (+2.13%)

NVST Envista
$40.91 /

-0.82 (-1.97%)

MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

SGH Smart Global
$48.71 /

-0.76 (-1.54%)

QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

PHR Phreesia
$55.13 /

-0.005 (-0.01%)

MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

Syndicate
Ionis Pharmaceuticals files to sell $500M of Convertible Senior Notes due 2026  16:38
04/06/21
04/06
16:38
04/06/21
16:38
IONS

Ionis Pharmaceuticals

$47.25 /

+0.35 (+0.75%)

 
ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.